TD Cowen analyst Michael Nedelcovych maintains Novo Nordisk (NYSE:NVO) with a Outperform and raises the price target from $105 to $115.
TD Cowen Maintains Outperform on Novo Nordisk, Raises Price Target to $115
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.